Entereg Scores Victory With Advisory Committee Vote

摘要

The FDA's Gastrointestinal Drugs Advisory Committee voted 9-6 that the overall benefits of Adolor and GlaxoSmithKline's Entereg outweigh its potential risks in the treatment of postoperative ileus (POI). If approved for POI, Entereg (alvimopan) would have a potential population of 350,000-360,000 patients, Adolor said. The FDA action date is Feb. 10.